Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of cancer called Diffuse Large B-Cell Lymphoma (DLBCL). The study is testing a new treatment called zilovertamab vedotin, also known by its code name MK-2140. This treatment will be combined with other medications, including rituximab, cyclophosphamide, doxorubicin, and prednisone. These medications are part of a standard treatment regimen known as R-CHP. The study will compare this new combination to the standard treatment regimen called R-CHOP, which includes the same medications plus an additional drug called vincristine.

The purpose of the study is to see if the new combination of treatments can help people with DLBCL live longer without their disease getting worse. Participants in the study will receive either the new treatment combination or the standard treatment. The study will last for up to 18 months, during which participants will receive their assigned treatment and be monitored regularly. The study will also look at how the treatments affect participants’ quality of life and any side effects they may experience.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of their disease. These tests may include imaging scans and blood tests. The study aims to provide valuable information about the effectiveness and safety of the new treatment combination for people with DLBCL.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of diffuse large B-cell lymphoma (DLBCL) through a prior biopsy and ensuring no previous treatment for DLBCL has been received.

A positron emission tomography (PET) scan is performed to confirm disease presence, and an evaluation of general health status is conducted, including heart function tests.

2 randomization

Participants are randomly assigned to one of two treatment groups. One group receives zilovertamab vedotin in combination with R-CHP, while the other group receives R-CHOP.

3 treatment administration

Treatment involves a combination of medications administered over a series of cycles. The medications include rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisolone, and vincristine, all given intravenously, except for prednisolone, which is taken orally.

The specific dosage and frequency of each medication are determined by the study protocol and are administered under medical supervision.

4 monitoring and follow-up

Regular monitoring is conducted to assess the response to treatment and any side effects. This includes imaging tests and health assessments.

Participants are evaluated for progression-free survival and overall survival, as well as any adverse events experienced during the study.

5 end of treatment evaluation

At the end of the treatment period, a comprehensive evaluation is conducted to determine the complete response to treatment.

Health-related quality of life is assessed using specific questionnaires to evaluate physical and emotional well-being.

Who Can Join the Study?

The patient must have a confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL), which is a type of cancer, based on a previous biopsy.
The patient must have a positive result on a positron emission tomography (PET) scan at the start of the study. This means the scan shows a score of 4 to 5 on a specific scale used to measure disease activity.
The patient must not have received any previous treatment for their DLBCL.
The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. This is a scale that measures how well a patient can perform daily activities, with 0 being fully active and 2 being able to do some activities but not work.
The patient must have a heart ejection fraction of 45% or higher. This is a measure of how well the heart is pumping blood, determined by tests like an echocardiogram (ECHO) or a multigated acquisition (MUGA) scan.
If the patient is infected with human immunodeficiency virus (HIV), their HIV must be well controlled with medication.
If the patient has a positive test for hepatitis B surface antigen (HBsAg), they can participate if they have been treated for hepatitis B and have no detectable virus in their blood before starting the study.
If the patient has a history of hepatitis C virus (HCV) infection, they can participate if there is no detectable virus in their blood at the start of the study.
Both male and female patients are eligible to participate.

Who Cannot Join the Study?

Patients with medical conditions other than Diffuse Large B-Cell Lymphoma (DLBCL) cannot participate. DLBCL is a type of cancer that affects the lymphatic system, which is part of the body’s immune system.
Patients who are not within the specified age range for the study cannot participate. The age range is typically defined by the study and may include specific age groups.
Patients who are part of a vulnerable population, such as those who may not be able to give informed consent, cannot participate. This is to ensure the safety and well-being of all participants.
Patients who do not meet other specific criteria set by the study, which may include health status, previous treatments, or other medical conditions, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Unidade Local De Saúde De Santa Maria, E.P.E.	Lisbon	Portugal
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
University Hospital Of Clermont-Ferrand	Clermont Ferrand	France
CHU Grenoble Alpes	La Tronche	France

Other Sites

Site Name	City	Country
Centre Antoine Lacassagne	Nice	France
Ospedale San Raffaele S.r.l.	Milan	Italy
Istituto Europeo Di Oncologia S.r.l.	Milan	Italy
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Del Mar	Barcelona	Spain
Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.	Porto	Portugal
Centre Hospital Region Metz Thionville	Metz	France
Hospital Universitario De Cruces	Barakaldo	Spain
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca	Cluj Napoca	Romania
Centre Hospitalier Groupe Hospitalier De La Rochelle Re Aunis	La Rochelle	France
Complejo Hospitalario Universitario Insular Materno Infantil	Las Palmas De Gran Canaria	Spain
Wojewodzki Szpital Specjalistyczny Im. Janusza Korczaka W Slupsku Sp. z o.o.	Slupsk	Poland
Semmelweis University	Budapest	Hungary
Czonyu Hgprnffbopf Dbxblonnqglyy Vgwldx	La Roche sur Yon	France
Ezxjeuibmovh Saah	Athens	Greece
Uqvuygbhlu Or Dekgxhvs	Debrecen	Hungary
Lxpnb Gdbbsyh Hbzahtjt Ow Amvfgf	Athens	Greece
Oqpcrn Ufyizfvnap Hpedyvnq	Odense	Denmark
Urultxpvgtgsnulrj Pmkaxeuxlmi Dysor Mysqpg	Ancona	Italy
Alwmeae Udhelwmcbr Hmcuhvkq	Aalborg	Denmark
Clqmdc Hqlecuztbtm Da Lr Cloy Bejevy	Bayonne	France
Uyvetygptz Ghrwnmq Hgvofctt Op Alnslcjyumjkzo	Alexandroupoli	Greece
Aahurne Ocbfejiohljvksynrsjvlowiq Mhanceyb Dwizd Cohwvu	Novara	Italy
Hdggniiz Uvaqkdgyavywr Phrfqa Dy Haumzh Da Mkukxadnbqw	Majadahonda	Spain
Hbqjdotm Udrhjxclvulwy 1j Dv Oaegkax	Madrid	Spain
Izwrszzw Cznxxn Dtovsqpntsdvnikac	L'hospitalet De Llobregat	Spain
Updyfkecyv Duvas Svrnf Dt Bhleihk	Brescia	Italy
Fyjczvuyh Pxfe Le Itiozxchsnwmv Baisrgiaz Dkp Hdbxxrox Uqypzotttezll Lh Pna	Madrid	Spain
Cwrz Cvesrm Cjhrxpa Afpwqbmwm Bzqrc Altvsoxhpo	Braga	Portugal
Fncxnmbroc Ifirl Sai Gfvcawn Dko Tfqszlu	Monza	Italy
Sgeflar Ktgzusdcy Mianxnpksdmx Smhoh Wfiagifchisp I Abzxfiukgkxht Z Wclafltftsiacpoepbb Cczzble Owrliascs W Ooxyodvmg	Olsztyn	Poland
Hmfgwetb Uekrbedcaxvrr Vcdeud Dn Lm Vyhazmzh	Malaga	Spain
Clfqoa Hmdlgexnvsh D Aoovgru	Avignon	France
Cvccdm Htsnn Bevrnfogj	Rouen	France
Pcvqge Hvxnshgrmza Sed z ocxi	Katowice	Poland
Hkz Socivg Aykn	Toulon	France
Tnrnv Veqyihvvl Bprxrhf Jcuky Kmeplw	Szekszard	Hungary
Onynrvml Odpoyfqwly Imynqzv	Budapest	Hungary
Aolskiv Onrvbjmtzrr Owxiccjz Ryucmph Vgfsg Sgnex Ctvbrvkr	Palermo	Italy
Lmdibgfcm Atlsoxpng Lbwzbe	Dunkirk	France
Iztok Crwc	Rionero In Vulture	Italy
Cfwdot Hhglscffqsj Ec Uvqebmluxmpby Dk Lfwujyg	Limoges	France
Couvqv Hvwfqxkbddx Ukswnwhhezdpn Di Dpfqr	Dijon	France
Ixnyjcuy Du Ctxecwyo Fttfosilzq Dqw Pfbmwjyp Pgw Lkwiwuzwdd Igofn	Candiolo	Italy
Mudezjx Mjwmfzf Cpbdbe	Amersfoort	The Netherlands
Siamqxplvxaqwogmikdbva Vprfszzxj Omedygzhkvrq	Nyiregyhaza	Hungary
Sqefnzfwenj Pbexwrxwh Sjntlli Kwpqqdapt Nk 1 W Lxqrjaxk	Lublin	Poland
Spuswcip Cqxzxp Jympypwx Dp Udqnmom Smjlr	Sibiu	Romania
Llpri Uzivnormhuyn Mmlrofu Cobonhd (otqie	Leiden	The Netherlands
Ezftzqr	Mechelen	Belgium
Audsxb Slbfymdsle Zzqdnfgcei	Dordrecht	The Netherlands
Can Hledmj	Mons	Belgium
Amsijo Uwsvcdwacg Hjdfmnsg	Aarhus	Denmark
Ravbit Mujihrclfza	Herning	Denmark
Idfymqef Cnldd &uwkuwg Sgtk Szrixyfyrag	Saint-Cloud	France
Ultewgobvr Gifmntp Hldsrftq Akkcvaw	Athens	Greece
Asguznt Uaznq Samvxrksn Lanydm Dtkhl Rxwgglb	Ravenna	Italy
Nktrjdef Icwjxmvc Oxyyzqftz Isk Miwml Sldjtzxynpwuxptxeg Pcmskpegb Ikhbwqsw Boqywptc	Gliwice	Poland
Pendat Senq	Wroclaw	Poland

Trial status

Country	Status	Recruitment Start
Belgium	Recruiting	28.03.2025
Denmark	Recruiting	28.03.2025
France	Recruiting	28.03.2025
Greece	Recruiting	28.03.2025
Hungary	Recruiting	28.03.2025
Italy	Recruiting	28.03.2025
Poland	Recruiting	28.03.2025
Portugal	Recruiting	28.03.2025
Romania	Recruiting	28.03.2025
Spain	Recruiting	28.03.2025
The Netherlands	Recruiting	28.03.2025

Trial locations

Investigated Drugs:

Zilovertamab Vedotin (MK-2140) is an experimental medication being tested in this clinical trial. It is designed to target and destroy cancer cells in patients with diffuse large B-cell lymphoma (DLBCL). The medication works by attaching to specific proteins on the surface of cancer cells, delivering a toxic substance directly to them, which helps to kill the cancer cells while minimizing damage to normal cells.

R-CHP is a combination of medications used to treat diffuse large B-cell lymphoma. It includes three chemotherapy drugs and a monoclonal antibody. The chemotherapy drugs work by stopping the growth of cancer cells, while the monoclonal antibody helps the immune system recognize and attack the cancer cells.

R-CHOP is another combination of medications used as a standard treatment for diffuse large B-cell lymphoma. It includes the same components as R-CHP, with the addition of a fourth chemotherapy drug. This combination works to kill cancer cells and support the immune system in fighting the cancer.

Investigated Diseases:

Diffuse large B-cell lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) – This is a type of non-Hodgkin lymphoma, which is a cancer that starts in white blood cells called lymphocytes. It is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. DLBCL can occur in any part of the body and often presents with symptoms such as swollen lymph nodes, fever, night sweats, and weight loss. The disease progresses quickly, and without intervention, it can spread to other parts of the body. It is the most common type of non-Hodgkin lymphoma in adults. The progression of DLBCL can vary, with some cases responding well to treatment while others may be more aggressive.

Trial ID:

2024-515566-13-00

Protocol code:

MK-2140-010

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?